EU Clinical Trial 2017-005076-26

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors  Apr 16, 2019

Main objective of the trial: This study will evaluate the antitumor activity, safety, and pharmacokinetics (PK) of tisotumab vedotin in patients with locally advanced or metastatic tumors.

Parties

Sponsors
Countries
CA DE ES FR GB IT US
Keywords
Colorectal adenocarcinoma Colorectal cancer metastatic Colorectal cancer stage IV Colorectal neoplasms malignant Head and neck cancer metastatic Head and neck cancer stage III Head and neck cancer stage IV HuMax-TF-ADC Metastatic colorectal cancer Non-small cell lung cancer Non-small cell lung cancer metastatic Non-small cell lung cancer stage IIIB Non-small cell lung cancer stage IV Pancreatic adenocarcinoma Pancreatic adenocarcinoma metastatic Pancreatic adenocarcinoma non-resectable Pancreatic cancer Pancreatic cancer metastatic Pancreatic cancer non-resectable Pancreatic carcinoma Pancreatic carcinoma metastatic Pancreatic carcinoma stage IV Pancreatic carcinoma stage IVA Pancreatic carcinoma stage IVB Pancreatic neoplasm Progression of non-small cell lung cancer TISOTUMAB VEDOTIN Tisotumab vedotin

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.